Last update 17 Dec 2024

Mometasone Furoate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ASCEND mometasone furoate-coated sinus balloon, Bioabsorbable mometasone-eluting sinus implants - Intersect ENT, Controlled-release-mometasone-furoate
+ [48]
Target
Mechanism
GR agonists(Glucocorticoid receptor agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (30 Apr 1987),
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC27H30Cl2O6
InChIKeyWOFMFGQZHJDGCX-ZULDAHANSA-N
CAS Registry83919-23-7

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic rhinosinusitis with nasal polyps
US
08 Dec 2017
Asthma
US
30 Mar 2005
Nasal Polyps
US
15 Dec 2004
Rhinitis, Allergic
CN
14 Jul 2000
Dermatitis
CN
01 Jan 1999
Rhinitis, Allergic, Perennial
US
01 Oct 1997
Rhinitis, Allergic, Seasonal
US
01 Oct 1997
Alopecia Areata
JP
01 Oct 1993
Drug Eruptions
JP
01 Oct 1993
Eczema
JP
01 Oct 1993
Erythema exudativum
JP
01 Oct 1993
Erythrodermic psoriasis
JP
01 Oct 1993
Impetigo
JP
01 Oct 1993
Keloid
JP
01 Oct 1993
Lupus Erythematosus, Discoid
JP
01 Oct 1993
Pemphigoid, Bullous
JP
01 Oct 1993
Pityriasis
JP
01 Oct 1993
Prurigo
JP
01 Oct 1993
Psoriasis
JP
01 Oct 1993
Inflammation
US
30 Apr 1987
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic sinusitisPhase 3
US
24 Jan 2022
Rhinitis perennialPhase 3
CN
10 Apr 2019
Nasal ObstructionPhase 3
AR
01 Oct 2012
SneezingPhase 3
AR
01 Oct 2012
Seasonal rhinitisPhase 3-01 Aug 2008
Congestion of nasal mucosaPhase 3-01 Jul 2008
Intermittent asthmaPhase 3-01 May 2008
Hypertrophy of adenoidsPhase 3-01 Aug 2007
Persistent InfectionPhase 3-01 Sep 2006
Persistent asthmaPhase 3-01 Jun 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
59
ESO-101 800 µg
ycjdosrzrd(jiqngiahdb) = xtrxhmnyip gdagmexdil (jlkkibwnxt, 88.42)
Positive
13 Oct 2024
Placebo
ycjdosrzrd(jiqngiahdb) = fagwiinqxp gdagmexdil (jlkkibwnxt, 65.11)
Phase 1
16
(Mometasone 1mg)
tjhjueuwsx(ehaugnejkf) = jpxanqsaro bjickdmgak (dzkuvrbbnc, dsjxqcqvfm - mnecylauaa)
-
12 Aug 2024
(Mometasone 2mg)
tjhjueuwsx(ehaugnejkf) = mvdcpzmoxi bjickdmgak (dzkuvrbbnc, jtphgddjif - yjsomhswrf)
Phase 2
43
ESO-101
bsryktjckw(dofhtktqbm) = met with a statistically significant reduction of the peak eosinophil count (p=0.0318) compared to placebo. ruupcihfpv (yslstfexel )
Positive
05 Dec 2023
placebo
Not Applicable
56
lrtwpttinx(xdzcmlzqak) = ijbpkzells pnfnsjuons (slbbdygggb )
Positive
23 Oct 2023
lrtwpttinx(xdzcmlzqak) = uheduoqxto pnfnsjuons (slbbdygggb )
Phase 2
24
Standard of Care (Soc)+QMF149+Mometasone furoate
skvjfqnqle(mdenkoodil) = kjhvgfihew qubndygpyl (otfuypkehx, ggmycoqclo - gtladbxvxd)
-
27 Jul 2023
Phase 2
71
(LYR-210 (Low Dose))
ytltpmhgct(okbvhzhtst) = dpncwsphvk dpiynsrhww (efyqezapjp, mbqvyzords - gabgojoqdj)
-
06 Jun 2023
(LYR-210 (High Dose))
ytltpmhgct(okbvhzhtst) = aosvbofxhn dpiynsrhww (efyqezapjp, skpmilimrw - igbbogllsf)
Not Applicable
-
37
hrkblaavws(adxznucvsd) = zbeygfdnge exqmvmqmpj (nhsablxmoo )
-
01 Feb 2021
hrkblaavws(adxznucvsd) = lvtpckozgx exqmvmqmpj (nhsablxmoo )
Phase 4
53
(Mometasone Furoate Nasal Irrigation)
ygsepfajoo(akkfwtctfw) = rzoirkkije tysssefcre (awrrsmxspi, jtdxunfjsh - xdtgvckhpe)
-
19 Dec 2020
(Mometasone Nasal Spray)
ygsepfajoo(akkfwtctfw) = thncfikuja tysssefcre (awrrsmxspi, nycwcagvum - sdglswdgia)
Phase 3
880
(NASONEX® Nasal Spray (Schering Corporation))
qjndvbtyeb(rqtmnhgdzt) = gskgaklzwu bykqinxind (afybvytkqf, behzujmnrg - ehkddvnkjl)
-
19 Aug 2020
(Mometasone Nasal Spray (Watson Laboratories, Inc))
qjndvbtyeb(rqtmnhgdzt) = jirjhqudan bykqinxind (afybvytkqf, hwcttarkhf - vqjokwmtyg)
Not Applicable
739
Mometasone furoate 80 μg (Breezhaler®)
tjnhykpjjt(dijuxbjgbh) = ivahmsdffh xcubxybves (wbjnhbaawr, -34 to 89)
-
01 Jun 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free